drugset / Trial / NCT00387894
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 2
Terminated
6 enrolled
Michael Prados
Genentech, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent glioblastoma multiforme or gliosarcoma.
Timeline
- Start
- 2007-01
- Primary completion
- 2009-03
- Completion
- 2009-03
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient accrual of population likely to benefit; progression in 6 patients”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 200 mg | Oral |
| Subject | Erlotinib | Small molecule | 650 mg | Oral |